[1] TANEJA SS.Urological oncology:prostate cancer[J].J Urol,2021,206(2):476-479.
[2] KOTAMARTI S,ARMSTRONG AJ,POLASCIK TJ,et al.Molecular mechanisms of castrate-resistant prostate cancer[J].Urol Clin North Am,2022,49(4):615-626.
[3] HARRIS AE,METZLER VM,LOTHION-ROY J,et al.Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer[J].Front Endocrinol (Lausanne),2022,13:1006101.
[4] SHI ZF,CHEN J,WUMANER A,et al.A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer[J].Biochem Biophys Res Commun,2021,5(37):78-84.
[5] LIANG D,TIAN CJ,ZHANG XW.lncRNA MNX1-AS1 promotes prostate cancer progression through regulating miR-2113/MDM2 axis[J].Mol Med Rep,2022,26(1):261-270.
[6] KARTHIKEYAN SK,XU N,FERGUSON RJ,et al.Identification of androgen response-related lncRNAs in prostate cancer[J].Prostate,2023,83(6):590-601.
[7] SIEGEL RL,WAGLE NS,CERCEK,et al.Colorectal cancer statistics,2023[J].CA-Cancer J Clin,2023,73(3):233-254.
[8] WANG EC,LEE WR,ARMSTRONG AJ.Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer[J].Prostate Cancer Prostatic Dis,2023,26(1):30-40.
[9] JI Y,ZHANG RU,HAN XL,et al.Targeting the N-terminal domain of the androgen receptor:The effective approach in therapy of CRPC[J].Eur J Med Chem,2023,247(11):50-77.
[10] CARAMELLA I,DALLA VA,BERGAMINI M,et al.Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer:that is the question[J].Endocrine,2022,78(3):441-445.
[11] NAITO Y,KATO M,KAWANISHI H,et al.Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer[J].Prostate,2023,83(4):307-315.
[12] ZHANG M,SUN Y,HUANG CP,et al.Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression[J].Cell Death Dis,2021,12(10):855-865.
[13] LI ZH,TENG JF,JIA ZM,et al.The long non-coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling[J].Journal of Clinical Laboratory Analysis,2021,35(2):749-757.
[14] KUMAR S,PRAJAPATI KS,SINGH AK,et al.Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer[J].Cancer Lett,2021,504(1):15-22.
[15] ZHANG BY,ZHANG MP,SHEN CY,et al.LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance[J].Cell Death Dis,2021,12(10):856-862.
[16] ZHANG BY,PITCHIAYA S,CIESLIK M,et al.Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression[J].Nature Genetics,2018,50(6):814-824.
[17] HUSEYNOVA G,ZGR E,BILGICGAZIOGLU S,et al.Androgen receptor blockade using enzalutamide suppresses long non-coding RNA ARLNC1 in prostate cancer cells[J].Cell Journal (Yakhteh),2022,24(12):774-778.